Skip to content
Search

Latest Stories

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Recognizing the importance of Pharmacy First service for both patients and primary care capacity, £215 million extra funding has been allocated to facilitate its continued growth.

Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.


This funding is in addition to the Community Pharmacy Contractual Framework (CPCF) allocations for 2024/25 and 2025/26.

“I feel strongly that pharmacy first has huge potential, but I think it hasn't realized its full potential because we've had to learn through its implementation, what has worked and what hasn't worked so well,” Kinnock told Pharmacy Business, during a media briefing yesterday.

“We're a government that takes decisions and makes policy on the basis of evidence. We have gathered the evidence, we've looked at the challenges, and we've spoken with the sector.”

“We've got the feedback on what we need to do to incentivize pharmacists on Pharmacy First and how we can also give them the space to do that,” he said.

He added that the £215 million allocation for Pharmacy First includes technical adjustments, such as changes to thresholds and fee rates.

Pharmacy First: Key changes coming in 2025

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

Starting in June 2025, contractors who deliver a Minimum Activity Requirement of 20-29 Clinical Pathway consultations in a month will receive a fixed payment of £500, while those completing 30 or more consultations will receive the maximum payment of £1,000.

Additionally, the claim window for Pharmacy First will be reduced to one month from June to enable the variable payment.

To qualify for the fixed payment from June 2025, contractors must be registered and able to deliver the Pharmacy First Service, in addition to meeting the Minimum Activity Requirement for Clinical Pathways consultations.

“As is currently the case, only consultations under the Clinical Pathways element of Pharmacy First will count towards eligibility for the initial and ongoing fixed payments,” DHSC said in a letter to the contractors.

Meanwhile, NHS England has conducted a clinical review of the Clinical Pathways, with updated versions set to be published soon. The cost control mechanism linked to Pharmacy First will also be maintained to ensure service growth remains within the agreed funding envelope.

“We have agreed to maintain the current cost control mechanism linked to Pharmacy First, which will manage growth of the service to ensure delivery remains within the agreed funding envelope,” DHSC noted.

New CPCF funding

The funding guaranteed to the community pharmacy sector through the Community Pharmacy Contractual Framework (CPCF) has increased to £2.698 billion for 2024/25 and will rise further to £3.073 billion in 2025/26.

Additionally, the Department of Health has agreed to a one-off write-off of £193 million in medicines margin over-delivery.

Announcing the funding boost, Kinnock expressed gratitude to Janet Morrison and the Community Pharmacy England (CPE) team for “a constructive, positive partnership-based engagement throughout this process.”

“I think the fact that we've got to where we are today is due in very large part to the approach and the whole constructive attitude that we've had with the sector,” he said.

Kinnock noted that the initiatives and measures announced demonstrate the government’s long-term commitment to “rebuilding community pharmacy and delivering more services.”

When asked where the money has come from, Kinnock said: “This funding has come from the financial envelope negotiated between the DHSC and Treasury for DHSC overall budget.”

Alette Addison, deputy director for pharmacy, eye care and controlled drugs at the Department of Health and Social Care (DHSC), acknowledged that pharmacies dispensing at a loss happens when “there's not enough margin in the system.”

“This deal puts 900 million into margin, so we've increased it by £100 million on the five-year deal. And the work that we will also do to improve that system should help put a little bit more cushioning between the prices that the pharmacies pay and the prices they are reimbursed,” she added.

CPE chief executive Janet Morrison added that there's a lot of programme of work to be carried out in collaboration with the Department of Health, including reviewing distribution, branded medicines, and generics.

“We will be working very hard with the department, and we'll also hold their feet to the fire to ensure those commitments are followed through,” she stated, adding, "there’s a lot of work to be done."

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less